Workflow
三十载创新跨越,默克全程守护促“新生”

Core Viewpoint - The article emphasizes the importance of assisted reproductive technology (ART) in addressing the declining birth rates in China, highlighting the advancements in medical technology and the comprehensive solutions provided by companies like Merck to support couples facing infertility challenges [1][4][10]. Group 1: Assisted Reproductive Technology Development - Over the past three years, China's population has shown a negative growth trend, making ART a crucial element in national economic and social development [1]. - Merck has successfully assisted in the birth of over 6 million babies through ART globally, showcasing its leadership in the field [1][2]. - The evolution of ART in China has transitioned from merely achieving pregnancy to ensuring healthy pregnancies, reflecting a significant qualitative leap in the technology [4]. Group 2: Innovations and Product Offerings - Merck's product portfolio includes the first approved recombinant gonadotropin and the first recombinant human luteinizing hormone, providing comprehensive treatment solutions for infertility [1][2]. - The drug Gonal-f®, launched in 1995, has been clinically validated for 30 years and has contributed to the successful births of over 6 million babies [2]. - Merck is introducing innovative products like the combination of recombinant human follicle-stimulating hormone and luteinizing hormone, which is set to be launched in China in 2025 [10][12]. Group 3: Quality Control and Patient Care - The establishment of a quality management system is essential for improving the success rates of ART and ensuring patient safety [6]. - Merck emphasizes personalized treatment plans and comprehensive patient care, integrating psychological support and health consultations into the ART process [8][9]. - Data-driven approaches are being utilized to enhance quality control and provide individualized care for patients undergoing ART [5]. Group 4: Public Awareness and Education - There is a significant gap in awareness regarding infertility issues, with only 50% of women seeking medical help despite 18% experiencing some form of infertility [8]. - Merck is actively involved in public education initiatives to raise awareness about fertility and the importance of early intervention [9]. - The company supports health promotion actions aimed at improving reproductive health and encouraging proactive fertility planning among women [9]. Group 5: Future Directions and Collaborations - The assisted reproductive industry in China is poised for a new phase of development, focusing on precision, intelligence, and humanization [11]. - Merck aims to enhance collaboration with local partners to improve ART success rates and patient experiences [12]. - The company is committed to advancing the ART field in China, aligning with the "Healthy China" strategic goals [13].